Literature DB >> 23311575

Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.

Ioannis F Voutsas1, Louisa G Mahaira, Katerina Fotopoulou, Nikiforos Kapranos, John G Reclos, Angelos D Gritzapis, Michail Papamichail, Sonia A Perez, Constantin N Baxevanis.   

Abstract

PURPOSE: Overexpression of human epidermal growth factor receptor-2 (HER-2/neu) in breast cancer patients is a prerequisite for treatment with trastuzumab. In the present study, we demonstrate by fluorescence in situ hybridization (FISH) analysis that HER-2/neu gene amplification and chromosome 17 (CEP17) polysomy can be induced by irradiation in human breast cancer cell lines with low basal level of HER-2/neu.
MATERIALS AND METHODS: The irradiation-induced HER-2/neu gene amplification and CEP17 polysomy enhanced HER-2/neu at the protein level in both human MDA-MB-231 and MDA-MB-435 breast cancer cell lines which was determined by immunohistochemistry and fluorescence analysis and was correlated with mRNA levels.
RESULTS: Irradiation affected to a high degree the responsiveness of both cell lines to in vitro treatment with trastuzumab. The direct antiproliferative effect of trastuzumab, as well as its capacity to induce natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), was considerably higher in the irradiated tumor cells compared to their non-irradiated counterparts.
CONCLUSION: Our data demonstrate that irradiation induces HER-2/neu gene amplification and CEP17 polysomy thereby enhancing expression of this protein in breast cancer cell lines rendering them susceptible to treatment with trastuzumab. They also suggest that patients with HER-2/neu negative inoperable tumors undergoing local radiation therapy may benefit from treatment with trastuzumab.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23311575     DOI: 10.3109/09553002.2013.765617

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  7 in total

1.  A rare complication resulting in a rare disease: radiation-induced male breast cancer.

Authors:  Jamila Alazhri; Constantine Saclarides; Eli Avisar
Journal:  BMJ Case Rep       Date:  2016-04-15

2.  Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.

Authors:  Julie A Carlson; Zohra Nooruddin; Chad Rusthoven; Anthony Elias; Virginia F Borges; Jennifer R Diamond; Brian Kavanagh; Peter Kabos
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

3.  BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

Authors:  Satyajit Patra; Vanesa Young; Leslie Llewellyn; Jitendra N Senapati; Jesil Mathew
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27

Review 4.  The Current Landscape of Antibody-based Therapies in Solid Malignancies.

Authors:  Ashu Shah; Sanchita Rauth; Abhijit Aithal; Sukhwinder Kaur; Koelina Ganguly; Catherine Orzechowski; Grish C Varshney; Maneesh Jain; Surinder K Batra
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 5.  NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

Authors:  Wei Wang; Amy K Erbe; Jacquelyn A Hank; Zachary S Morris; Paul M Sondel
Journal:  Front Immunol       Date:  2015-07-27       Impact factor: 7.561

6.  Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.

Authors:  M M Wattenberg; A R Kwilas; S R Gameiro; A P Dicker; J W Hodge
Journal:  Br J Cancer       Date:  2014-02-20       Impact factor: 7.640

7.  Three-dimensional microtissues essentially contribute to preclinical validations of therapeutic targets in breast cancer.

Authors:  Natalie Falkenberg; Ines Höfig; Michael Rosemann; Justine Szumielewski; Sabine Richter; Kenji Schorpp; Kamyar Hadian; Michaela Aubele; Michael J Atkinson; Nataša Anastasov
Journal:  Cancer Med       Date:  2016-01-14       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.